Charles Lazelle Sawyers

US Patent:

7709517, May 4, 2010

Filed:

May 15, 2006

Appl. No.:

11/433829

Inventors:

Charles L. Sawyers - New York NY, US
Michael E. Jung - Los Angeles CA, US
Charlie D. Chen - Los Angeles CA, US
Samedy Ouk - Costa Mesa CA, US
Derek Welsbie - Northridge CA, US
Chris Tran - New York NY, US
John Wongvipat - Nanuet NY, US
Dongwon Yoo - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/4166
C07D 233/02

US Classification:

514392, 5483001, 5483164, 5483171, 5483211, 514385, 514386

Abstract:

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

US Patent:

8110594, Feb 7, 2012

Filed:

Mar 29, 2007

Appl. No.:

11/730168

Inventors:

Michael E. Jung - Los Angeles CA, US
Dongwon Yoo - Los Angeles CA, US
Charles L. Sawyers - New York NY, US
Chris Tran - New York NY, US
John Wongvipat - New York NY, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/4166
C07D 233/86

US Classification:

514391, 5483211, 5483014

Abstract:

The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

US Patent:

8183274, May 22, 2012

Filed:

Feb 18, 2010

Appl. No.:

12/708523

Inventors:

Charles L. Sawyers - New York NY, US
Michael E. Jung - Los Angeles CA, US
Charlie D. Chen - Shanghai, CN
Samedy Ouk - Costa Mesa CA, US
Chris Tran - New York NY, US
John Wongvipat - Nanuet NY, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/4166
A61K 31/4184
C07D 233/86

US Classification:

514391, 5483211, 5483014

Abstract:

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

US Patent:

8445507, May 21, 2013

Filed:

Mar 27, 2007

Appl. No.:

12/294881

Inventors:

Michael E. Jung - Los Angeles CA, US
Charles L. Sawyers - New York NY, US
Samedy Ouk - Los Angeles CA, US
Chris Tran - New York NY, US
John Wongvipat - New York NY, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/4439
C07D 213/60

US Classification:

514278, 514341, 546 15, 5462741

Abstract:

A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.

US Patent:

8648105, Feb 11, 2014

Filed:

Dec 21, 2011

Appl. No.:

13/333543

Inventors:

Michael E. Jung - Los Angeles CA, US
Dongwon Yoo - Los Angeles CA, US
Charles L. Sawyers - New York NY, US
Chris Tran - New York NY, US
John Wongvipat - New York NY, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/4166
C07D 233/86

US Classification:

514389, 5483014, 5483171

Abstract:

The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

US Patent:

20070253953, Nov 1, 2007

Filed:

Dec 15, 2004

Appl. No.:

10/582841

Inventors:

Charlie Chen - Los Angeles CA, US
Charles Sawyers - New York NY, US

Assignee:

REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE - Oakland CA

International Classification:

A61K 39/395
C12Q 1/68

US Classification:

424138100, 435006000

Abstract:

The present invention relates to the identification a molecular signature for PTEN tumor suppressor. The molecular signature comprising a gene or genes that are of use for diagnosis, prognosis, drug research and development and therapeutics. Specifically, the present invention relates to identification of IGFBP2 gene, its mRNA and/or protein products that closely associate with PTEN mutations. The present invention further demonstrates that IGFBP2 expression is negatively regulated by PTEN, positively regulated by PI3K and Akt activation, that IGFBP2 plays a functional role in the PTEN signaling and is required for Akt transformation. The use of IGFBP2 gene, its gene product such as its RNA transcript, protein and molecular probes in diagnosis, prognosis, drug discovery and validation and therapeutic target and therapeutics is also contemplated.

US Patent:

20080299589, Dec 4, 2008

Filed:

Nov 8, 2004

Appl. No.:

11/667430

Inventors:

Charles L. Sawyers - New York NY, US
George V. Thomas - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 33/574
C12Q 1/02

US Classification:

435 723, 435 29

Abstract:

The invention disclosed herein provides methods for the examination and/or quantification of the PI3K/Akt and Ras/MAPK biochemical pathways that are disregulated in pathologies such as cancers of the prostate and gliomas. The invention disclosed herein further provides reagents and kits adapted for performing such methods.

US Patent:

20090111864, Apr 30, 2009

Filed:

Oct 24, 2008

Appl. No.:

12/257743

Inventors:

MICHAEL E. JUNG - Los Angeles CA, US
Dongwon Yoo - Los Angeles CA, US
Charles L. Sawyers - New York NY, US
Chris Tran - New York NY, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/4184
C07D 233/86
C07D 403/10
C07D 235/02
A61K 31/4166

US Classification:

514391, 5483211, 5483144, 5483014

Abstract:

The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.